Royalty Pharma plc filings document the company’s biopharmaceutical royalty business, public equity structure, governance, financing activity, and material events. Form 8-K reports furnish quarterly and annual results, including Portfolio Receipts, Royalty Receipts, operating cash flow, guidance, dividends, and developments affecting royalty and funding arrangements.
Regulation FD and material-agreement disclosures describe royalty transactions, synthetic royalty funding, senior secured loan arrangements, and portfolio-related clinical or regulatory events. Other filings cover Class A ordinary shares listed on Nasdaq, senior note issuances and related guarantees, annual meeting matters, board and compensation governance, shareholder voting items, and changes involving directors or officers.
TPC RP EPA1 LLC and TPC RP 2021 LLC reported multiple sales of Common Stock. The excerpt lists discrete market sales on several dates in 12/2025–02/2026, including transactions such as 108,759 shares for $4,659,572.71 on 02/03/2026 and 69,665 shares for $2,938,636.90 on 02/02/2026.
The filings show repeated, scheduled dispositions by affiliated entities rather than a single block sale; cash‑flow recipients are the named selling entities. Transaction timing and per‑trade amounts are shown inline with each sale record.
Royalty Pharma plc insider reporting shows entities associated with EVP & CFO Terrance P. Coyne selling Class A Ordinary Shares of the company. On the reported date, TPC RP 2021, LLC and TPC RP EPA1 LLC together sold 34,791 shares in open-market transactions at a weighted average price of $45.3165 per share.
The filing notes these transactions were carried out under a pre-established Rule 10b5-1 trading plan adopted on August 8, 2025, which automates sales based on preset instructions. A footnote explains the reported sale price is an average, with individual trades executed between $44.97 and $45.60 per share.
RPRX affiliates submitted notices of proposed sales of Common Stock under Rule 144, listing multiple planned transactions across late 2025 and early 2026. Examples include sales by TPC RP EPA1 LLC and TPC RP 2021 LLC, such as $1,268,311.44 for 01/02/2026 and $4,659,572.71 for 02/03/2026 respectively.
Royalty Pharma plc’s Class A shareholder updates 13D stake. R & H Trust Co. (Guernsey) Limited and Achille G. Severgnini report they may be deemed to beneficially own 24,223,082 Class A shares, representing 5.7% of Royalty Pharma’s outstanding Class A shares as of February 19, 2026.
The filing details holdings through sub-funds MGG Strategic and GG Strategic and extensive beneficial ownership disclaimers by the boards, trust beneficiaries, trustee and protector. It also notes prior sales and facility agreements that reduced pledged collateral shares and adjusted committed and uncommitted credit facility amounts.
Capital International Investors, a division of Capital Research and Management Company and affiliated investment management entities, reports beneficial ownership of 32,745,526 shares of Royalty Pharma PLC common stock, representing 7.7% of the 427,247,489 shares believed outstanding as of the event date.
The firm has sole voting power over 32,581,425 shares and sole dispositive power over 32,745,526 shares, with no shared voting or dispositive power. The securities are certified as acquired and held in the ordinary course of business, not for the purpose of changing or influencing control of Royalty Pharma.
Royalty Pharma CEO Pablo G. Legorreta acquired 157,828 Class A Ordinary Shares at $0.00 per share on February 11, 2026 through the settlement of equity performance awards. Following this exempt award, he directly holds 1,098,783 Class A Ordinary Shares.
He also has indirect ownership through various family trusts and entities, including Legorreta Children 2002 Trust, GST-Exempt Legorreta family trusts, Legorreta Investments LLC, Tata MC 35 Ltd., and accounts for spouse and children. In addition, he and related vehicles hold limited partnership interests in RPI US Partners 2019, LP exchangeable into 73,495,660 Class A Ordinary Shares and Class E Ordinary Shares of Royalty Pharma Holdings Ltd exchangeable into 13,356,742 Class A Ordinary Shares, with the Class E shares subject to vesting conditions.
Royalty Pharma plc executive vice president and CFO Terrance P. Coyne reported an indirect equity award of Class A Ordinary Shares. On February 11, 2026, an affiliated entity, TPC RP EPA1 LLC, acquired 26,626 Class A shares at $0 per share in an exempt transaction under Rule 16b-3 tied to the settlement of equity performance awards. Following this grant, TPC RP EPA1 LLC holds 49,511 Class A shares indirectly for Coyne. The filing also notes additional indirect holdings through related LLCs and retirement accounts, plus partnership and Class E Ordinary Share interests exchangeable into 6,448,180 and 1,807,277 Class A shares, respectively, with the Class E interests subject to vesting conditions.
Royalty Pharma plc EVP & Vice Chairman Christopher Hite reported an indirect acquisition of 26,626 Class A Ordinary Shares on February 11, 2026. The shares were granted at $0 per share in an exempt equity award settlement under Rule 16b-3.
After this transaction, 685,136 Class A Ordinary Shares are held indirectly through SCH Investment Partners LLC, and 70,000 Class A Ordinary Shares are held directly. In addition, family vehicles hold interests exchangeable into 866,410 Class A shares and Class E shares exchangeable into 1,238,789 Class A shares, with the Class E shares subject to vesting conditions.
Royalty Pharma plc EVP Marshall Urist reported an exempt acquisition of 19,970 Class A Ordinary Shares on February 11, 2026. The shares were granted at a price of $0.00 in connection with the settlement of equity performance awards, increasing his directly held Class A stake to 27,368 shares. In addition, 19,020 Class A Ordinary Shares are held indirectly through an IRA, highlighting a mix of direct and retirement-account ownership tied to his role as EVP, Research & Investments.
Royalty Pharma plc is the largest buyer of biopharmaceutical royalties, funding innovation by purchasing interests in drug sales from academic, biotech and large pharma partners. Its portfolio spans royalties on more than 35 marketed therapies and 20 development-stage product candidates.
In 2025, the company generated $3.3 billion of Portfolio Receipts, mainly cash flows from existing royalty investments, and announced transactions with total potential value of $4.7 billion, deploying $2.6 billion of cash into new royalties and related assets. The portfolio includes 16 therapies each with over $1 billion in 2025 end‑market sales, providing diversified exposure across rare disease, oncology, neuroscience, immunology and other areas.
Royalty Pharma emphasizes long-duration cash flows, selective capital deployment and a flexible structuring toolkit, including third‑party royalties, synthetic royalties and other funding arrangements. Key risks center on product sales performance, development‑stage failures, competition for royalties, leverage, and regulatory and market uncertainties in the global biopharmaceutical sector.